BioNTech Results Presentation Deck

Expanding Strategic Collaboration With Genmab GEN 1046 / BNT3111 Anti- PD-L1 орга Anti- 4-1BB Phase 2: R/R NSCLC Phase 1/2: Advanced solid tumors Bispecific antibody: Conditional 4-1 BB co-stimulation while blocking PD-(L)1 axis GEN 1042/BNT312¹ 21 1 Collaboration with Genmab based on 50/50 sharing of costs and profits 2 HexaBody® technology owned by Genmab Anti- CD40 Anti- 4-1BB RO Phase 1/2: Advanced solid tumors Bispecific antibody: Combines targeting and conditional activation of CD40 and 4-1BB on immune cells GEN1053/BNT3131 Phase 1/2: Solid tumors FPD expected in 2H 2022 Anti- CD27 Monospecific HexaBody2 targeting CD27 on naïve and activated T cells Next-generation immunomodulators designed to prime and activate anti-tumor T cell and Natural Killer cell function BIONTECH

View entire presentation